Klotho Neurosciences (KLTO)announced that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. platform technology.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences seeking to expand into adjacent technologies
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences partners with AAVnerGene to make gene therapy assets
- Klotho Neurosciences Regains Nasdaq Compliance
- Klotho Neurosciences regains compliance with Nasdaq